Status:

RECRUITING

Clinical Study Evaluating the Effect of Losartan

Lead Sponsor:

Tanta University

Conditions:

Pancreatic Cancer

Eligibility:

All Genders

50-85 years

Phase:

NA

Brief Summary

The pancreas is two organs packaged into one. The islets of Langerhans serve critical endocrine functions, and the exocrine portion is a major source of enzymes that are essential for digestion. Panc...

Detailed Description

Pancreatic cancer has multi step carcinogenesis, starting from Pancreatic Intra-ductal Neoplasia and ends with an invasive neoplastic lesion.Pancreatic cancer is most frequent in elder people; the ris...

Eligibility Criteria

Inclusion

  • Male and female pancreatic cancer patients aged ≥ 50 years old.
  • Hypertensive patient with BP ≥ 140/90 mm Hg.
  • Histologically confirmed metastatic pancreatic adenocarcinoma; or locally advanced pancreatic cancer patients.
  • All included patients must sign an informed consent

Exclusion

  • Patients with serious concomitant systemic disorders as significant cardiac, renal, hepatic, or pulmonary morbidity.
  • Pregnant or lactating women and women of childbearing potential.
  • Patients received prior systemic fluoropyrimidine therapy within the past 10 years.
  • Prior un-anticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-fluorouracil, irinotecan, oxaliplatin, losartan, or any monoclonal antibody.
  • Patients with an active, known, or suspected autoimmune disease such as psoriasis.
  • Patients with a known positive test for hepatitis B virus surface antigen (HBV s Ag) or hepatitis C virus (HCV antibody) and patients with a known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS).
  • Patients received a live vaccine or live attenuated vaccines as intranasal influenza vaccines within 30 days of the planned start of study therapy.

Key Trial Info

Start Date :

July 20 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 20 2026

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT06539806

Start Date

July 20 2024

End Date

August 20 2026

Last Update

August 6 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tanta University Hospital

Tanta, Egypt